#BEGIN_DRUGCARD DB03227

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
50383

# Chemical_Formula:
C11H16N2O8P

# Chemical_IUPAC_Name:
3-carbamoyl-1-[(2R,3R,4R,5S)-3,4-dihydroxy-5-[(phosphonooxy)methyl]oxolan-2-yl]-1$l^{5}-pyridin-1-ylium

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
3-Carbamoyl-1-beta-D-ribofuranosyl pyridinium hydroxide-5&#39;phosphate, inner salt. A nucleotide in which the nitrogenous base, nicotinamide, is in beta-N-glycosidic linkage with the C-1 position of D-ribose. Synonyms: Nicotinamide Ribonucleotide; NMN. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Nicotinamide Mononucleotide

# HET_ID:
NMN

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C11H15N2O8P/c12-10(16)6-2-1-3-13(4-6)11-9(15)8(14)7(21-11)5-20-22(17,18)19/h1-4,7-9,11,14-15H,5H2,(H3-,12,16,17,18,19)/p+1/t7-,8-,9+,11+/m0/s1

# InChI_Key:
InChIKey=DAYLJWODMCOQEW-WYOJIJJFSA-O

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3227

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
335.2271

# Molecular_Weight_Mono:
335.06442701

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1GZU

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-1.5

# Predicted_LogS:
-2.3

# Predicted_Water_Solubility:
1.80e+00 g/l

# Primary_Accession_No:
DB03227

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
6093202

# PubChem_Substance_ID:
46506664

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02366

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC(=O)C1=CC=C[N+](=C1)[C@@H]1O[C@@H](COP(O)(O)=O)[C@H](O)[C@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:02 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Nucleus

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
NMNAT1

# Drug_Target_1_GenBank_ID_Gene:
AF314163

# Drug_Target_1_GenBank_ID_Protein:
11245478

# Drug_Target_1_GeneCard_ID:
NMNAT1

# Drug_Target_1_Gene_Name:
NMNAT1

# Drug_Target_1_Gene_Sequence:
>840 bp
ATGGAAAATTCCGAGAAGACTGAAGTGGTTCTCCTTGCTTGTGGTTCATTCAATCCCATC
ACCAACATGCACCTCAGGTTGTTTGAGCTGGCCAAGGACTACATGAATGGAACAGGAAGG
TACACAGTTGTCAAAGGCATCATCTCTCCTGTTGGTGATGCCTACAAGAAGAAAGGACTC
ATTCCTGCCTATCACCGGGTCATCATGGCAGAACTTGCTACCAAGAATTCTAAATGGGTG
GAAGTTGATACATGGGAAAGTCTTCAGAAGGAGTGGAAAGAGACTCTGAAGGTGCTAAGA
CACCATCAAGAGAAATTGGAGGCTAGTGACTGTGATCACCAGCAGAACTCACCTACTCTA
GAAAGGCCTGGAAGGAAGAGGAAGTGGACTGAAACACAAGATTCTAGTCAAAAGAAATCC
CTAGAGCCAAAAACAAAAGCTGTGCCAAAGGTCAAGCTGCTGTGTGGGGCAGATTTATTG
GAGTCCTTTGCTGTTCCCAATTTGTGGAAGAGTGAAGACATCACCCAAATCGTGGCCAAC
TATGGGCTCATATGTGTTACTCGGGCTGGAAATGATGCTCAGAAGTTTATCTATGAATCG
GATGTGCTGTGGAAACACCGGAGCAACATTCACGTGGTGAATGAATGGATCGCTAATGAC
ATCTCATCCACAAAAATCCGGAGAGCCCTCAGAAGGGGCCAGAGCATTCGCTACTTGGTA
CCAGATCTTGTCCAAGAATACATTGAAAAGCATAATTTGTACAGCTCTGAGAGTGAAGAC
AGGAATGCTGGGGTCATCCTGGCCCCTTTGCAGAGAAACACTGCAGAAGCTAAGACATAG

# Drug_Target_1_General_Function:
Coenzyme transport and metabolism

# Drug_Target_1_General_References:
11248244	Schweiger M, Hennig K, Lerner F, Niere M, Hirsch-Kauffmann M, Specht T, Weise C, Oei SL, Ziegler M: Characterization of recombinant human nicotinamide mononucleotide adenylyl transferase (NMNAT), a nuclear enzyme essential for NAD synthesis. FEBS Lett. 2001 Mar 9;492(1-2):95-100.
11751893	Garavaglia S, D'Angelo I, Emanuelli M, Carnevali F, Pierella F, Magni G, Rizzi M: Structure of human NMN adenylyltransferase. A key nuclear enzyme for NAD homeostasis. J Biol Chem. 2002 Mar 8;277(10):8524-30. Epub 2001 Dec 19.
11891043	Fernando FS, Conforti L, Tosi S, Smith AD, Coleman MP: Human homologue of a gene mutated in the slow Wallerian degeneration (C57BL/Wld(s)) mouse. Gene. 2002 Feb 6;284(1-2):23-9.

# Drug_Target_1_HGNC_ID:
HGNC:17877

# Drug_Target_1_HPRD_ID:
16369

# Drug_Target_1_ID:
3296

# Drug_Target_1_Locus:
1p32-p35

# Drug_Target_1_Molecular_Weight:
31933

# Drug_Target_1_Name:
Nicotinamide mononucleotide adenylyltransferase 1

# Drug_Target_1_Number_of_Residues:
279

# Drug_Target_1_PDB_ID:
1KQO

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF01467	CTP_transf_2

# Drug_Target_1_Protein_Sequence:
>Nicotinamide mononucleotide adenylyltransferase 1
MENSEKTEVVLLACGSFNPITNMHLRLFELAKDYMNGTGRYTVVKGIISPVGDAYKKKGL
IPAYHRVIMAELATKNSKWVEVDTWESLQKEWKETLKVLRHHQEKLEASDCDHQQNSPTL
ERPGRKRKWTETQDSSQKKSLEPKTKAVPKVKLLCGADLLESFAVPNLWKSEDITQIVAN
YGLICVTRAGNDAQKFIYESDVLWKHRSNIHVVNEWIANDISSTKIRRALRRGQSIRYLV
PDLVQEYIEKHNLYSSESEDRNAGVILAPLQRNTAEAKT

# Drug_Target_1_Reaction:
ATP + nicotinamide ribonucleotide = diphosphate + NAD+

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
ATP + nicotinamide ribonucleotide = diphosphate + NAD(+)

# Drug_Target_1_SwissProt_ID:
Q9HAN9

# Drug_Target_1_SwissProt_Name:
NMNA1_HUMAN

# Drug_Target_1_Synonyms:
EC 2.7.7.1
NMN adenylyltransferase 1

# Drug_Target_1_Theoretical_pI:
9.24

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Nucleus (Probable)

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
NMNAT3

# Drug_Target_2_GenBank_ID_Gene:
AF345564

# Drug_Target_2_GenBank_ID_Protein:
14029540

# Drug_Target_2_GeneCard_ID:
NMNAT3

# Drug_Target_2_Gene_Name:
NMNAT3

# Drug_Target_2_Gene_Sequence:
>759 bp
ATGAAGAGCCGAATACCTGTGGTGCTCCTGGCCTGTGGCTCCTTTAACCCCATCACCAAC
ATGCACCTGCGCATGTTTGAGGTGGCCAGAGATCACCTACACCAAACAGGAATGTACCAG
GTCATCCAGGGTATCATCTCTCCTGTCAACGACACCTATGGGAAGAAAGACCTCGCAGCT
TCTCATCACCGAGTGGCCATGGCCCGGCTGGCCCTGCAGACATCCGACTGGATCCGGGTG
GACCCTTGGGAGAGTGAGCAGGCACAGTGGATGGAGACAGTGAAGGTGCTGAGGCATCAT
CACAGCAAACTGCTCAGATCTCCACCCCAGATGGAAGGCCCAGACCATGGCAAGGCACTC
TTCTCGACCCCTGCAGCTGTGCCTGAGCTGAAGCTTCTCTGTGGGGCAGACGTCTTGAAG
ACCTTCCAGACCCCCAACCTCTGGAAGGATGCGCACATCCAGGAAATAGTGGAGAAGTTT
GGCTTGGTGTGCGTGGGCCGAGTAAGTCACGACCCAAAAGGTTACATCGCAGAATCTCCC
ATCCTACGGATGCACCAGCACAACATTCACCTGGCCAAGGAGCCTGTGCAGAATGAGATC
AGTGCCACATACATCAGGCGAGCCTTGGGCCAAGGGCAGAGCGTAAAGTACCTGATTCCC
GATGCTGTCATCACGTACATCAAGGACCATGGCCTCTACACCAAGGGCAGTACCTGGAAA
GGCAAAAGCACCCAGAGCACTGAGGGCAAGACAAGCTAG

# Drug_Target_2_General_Function:
Coenzyme transport and metabolism

# Drug_Target_2_General_References:
Not Available

# Drug_Target_2_HGNC_ID:
HGNC:20989

# Drug_Target_2_HPRD_ID:
16370

# Drug_Target_2_ID:
3333

# Drug_Target_2_Locus:
3q23

# Drug_Target_2_Molecular_Weight:
28322

# Drug_Target_2_Name:
Nicotinamide mononucleotide adenylyltransferase 3

# Drug_Target_2_Number_of_Residues:
252

# Drug_Target_2_PDB_ID:
1NUU

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF01467	CTP_transf_2

# Drug_Target_2_Protein_Sequence:
>Nicotinamide mononucleotide adenylyltransferase 3
MKSRIPVVLLACGSFNPITNMHLRMFEVARDHLHQTGMYQVIQGIISPVNDTYGKKDLAA
SHHRVAMARLALQTSDWIRVDPWESEQAQWMETVKVLRHHHSKLLRSPPQMEGPDHGKAL
FSTPAAVPELKLLCGADVLKTFQTPNLWKDAHIQEIVEKFGLVCVGRVGHDPKGYIAESP
ILRMHQHNIHLAKEPVQNEISATYIRRALGQGQSVKYLIPDAVITYIKDHGLYTKGSTWK
GKSTQSTEGKTS

# Drug_Target_2_Reaction:
ATP + nicotinamide ribonucleotide = diphosphate + NAD+

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
ATP + nicotinamide ribonucleotide = diphosphate + NAD(+)

# Drug_Target_2_SwissProt_ID:
Q96T66

# Drug_Target_2_SwissProt_Name:
NMNA3_HUMAN

# Drug_Target_2_Synonyms:
EC 2.7.7.1
NMN adenylyltransferase 3

# Drug_Target_2_Theoretical_pI:
9.69

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Cell membrane
GPI-anchor
lipid-anchor

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
BST1

# Drug_Target_3_GenBank_ID_Gene:
D21878

# Drug_Target_3_GenBank_ID_Protein:
999429

# Drug_Target_3_GeneCard_ID:
BST1

# Drug_Target_3_Gene_Name:
BST1

# Drug_Target_3_Gene_Sequence:
>957 bp
ATGGCGGCCCAGGGGTGCGCGGCATCGCGGCTGCTCCAGCTGCTGCTGCAGCTTCTGCTT
CTACTGTTGCTGCTGGCGGCGGGCGGGGCGCGCGCGCGGTGGCGCGCGGAGGGCACCAGC
GCACACTTGCGGGACATCTTCCTGGGCCGCTGCGCCGAGTACCGCGCACTGCTGAGTCCC
GAGCAGCGGAACAAGAACTGCACAGCCATCTGGGAAGCCTTTAAAGTGGCGCTGGACAAG
GATCCCTGCTCCGTGCTGCCCTCAGACTATGACCTTTTTATTAACTTGTCCAGGCACTCT
ATTCCCAGAGATAAGTCCCTGTTCTGGGAAAATAGCCACCTCCTTGTTAACAGCTTTGCA
GACAACACCCGTCGTTTTATGCCCCTGAGCGATGTTCTGTATGGCAGGGTTGCAGATTTC
TTGAGCTGGTGTCGACAGAAAAATGACTCTGGACTCGATTACCAATCCTGCCCTACATCA
GAAGACTGTGAAAATAATCCTGTGGATTCCTTTTGGAAAAGGGCATCCATCCAGTATTCC
AAGGATAGTTCTGGGGTGATCCACGTCATGCTGAATGGTTCAGAGCCAACAGGAGCCTAT
CCCATCAAAGGTTTTTTTGCAGATTATGAAATTCCAAACCTCCAGAAGGAAAAAATTACA
CGAATCGAGATCTGGGTTATGCATGAAATTGGGGGACCCAATGTGGAATCCTGCGGGGAA
GGCAGCATGAAAGTCCTGGAAAAGAGGCTGAAGGACATGGGGTTCCAGTACAGCTGTATT
AATGATTACCGACCAGTGAAGCTCTTACAGTGCGTGGACCACAGCACCCATCCTGACTGT
GCCTTAAAGTCGGCAGCAGCCGCTACTCAAAGAAAAGCCCCAAGTCTTTATACAGAACAA
AGGGCGGGTCTTATCATTCCCCTCTTTCTGGTGCTGGCTTCCCGGACTCAACTGTAA

# Drug_Target_3_General_Function:
Involved in NAD+ nucleosidase activity

# Drug_Target_3_General_References:
8202488	Kaisho T, Ishikawa J, Oritani K, Inazawa J, Tomizawa H, Muraoka O, Ochi T, Hirano T: BST-1, a surface molecule of bone marrow stromal cell lines that facilitates pre-B-cell growth. Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5325-9.

# Drug_Target_3_HGNC_ID:
HGNC:1118

# Drug_Target_3_HPRD_ID:
02665

# Drug_Target_3_ID:
2290

# Drug_Target_3_Locus:
4p15

# Drug_Target_3_Molecular_Weight:
35724

# Drug_Target_3_Name:
ADP-ribosyl cyclase 2

# Drug_Target_3_Number_of_Residues:
318

# Drug_Target_3_PDB_ID:
1ISM

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF02267	Rib_hydrolayse

# Drug_Target_3_Protein_Sequence:
>ADP-ribosyl cyclase 2 precursor
MAAQGCAASRLLQLLLQLLLLLLLLAAGGARARWRGEGTSAHLRDIFLGRCAEYRALLSP
EQRNKNCTAIWEAFKVALDKDPCSVLPSDYDLFINLSRHSIPRDKSLFWENSHLLVNSFA
DNTRRFMPLSDVLYGRVADFLSWCRQKNDSGLDYQSCPTSEDCENNPVDSFWKRASIQYS
KDSSGVIHVMLNGSEPTGAYPIKGFFADYEIPNLQKEKITRIEIWVMHEIGGPNVESCGE
GSMKVLEKRLKDMGFQYSCINDYRPVKLLQCVDHSTHPDCALKSAAAATQRKAPSLYTEQ
RAGLIIPLFLVLASRTQL

# Drug_Target_3_Reaction:
NAD+ + H2O = ADP-ribose + nicotinamide

# Drug_Target_3_Signals:
1-28

# Drug_Target_3_Specific_Function:
Synthesizes cyclic ADP-ribose, a second messenger that elicits calcium release from intracellular stores. May be involved in pre-B-cell growth

# Drug_Target_3_SwissProt_ID:
Q10588

# Drug_Target_3_SwissProt_Name:
BST1_HUMAN

# Drug_Target_3_Synonyms:
ADP-ribosyl cyclase 2 precursor
BST- 1
Bone marrow stromal antigen 1
CD157 antigen
Cyclic ADP-ribose hydrolase 2
EC 3.2.2.5
cADPr hydrolase 2

# Drug_Target_3_Theoretical_pI:
7.86

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Cytoplasmic

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
Not Available

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
AE016830

# Drug_Target_4_GenBank_ID_Protein:
Not Available

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
ligA

# Drug_Target_4_Gene_Sequence:
>2031 bp
ATGGAACAACAACCATTAACATTAACGGCGGCGACAACTCGTGCGCAAGAATTAAGAAAA
CAACTCAATCAATATTCCCATGAATATTATGTCAAAGATCAACCATCCGTAGAAGATTAT
GTTTACGATCGTTTGTATAAAGAGTTAGTCGATATTGAAACGGAGTTTCCTGATTTAATC
ACGCCAGATTCGCCGACACAACGTGTAGGTGGCAAAGTTTTATCTGGTTTTGAAAAAGCT
CCGCATGACATTCCAATGTATAGTTTAAATGATGGGTTTAGCAAGGAAGACATTTTTGCT
TTTGATGAACGTGTTCGTAAGGCGATTGGTAAACCCGTTGCTTACTGTTGTGAGTTAAAA
ATTGATGGGTTAGCAATTTCATTACGTTATGAAAACGGGGTGTTTGTACGCGGAGCAACA
CGAGGCGATGGAACGGTTGGTGAAAACATTACAGAGAACTTACGAACGGTTCGCTCTGTA
CCGATGCGTTTAACGGAGCCCATTTCAGTGGAAGTTCGTGGCGAGTGCTACATGCCTAAA
CAATCCTTTGTCGCATTGAATGAAGAACGTGAAGAAAATGGCCAAGATATTTTTGCCAAT
CCTCGGAATGCAGCGGCGGGAAGCTTGCGCCAACTAGATACAAAAATTGTGGCTAAACGG
AACTTAAATACGTTTTTATACACAGTTGCTGACTTTGGACCAATGAAAGCGAAGACGCAG
TTTGAGGCATTAGAAGAGCTTTCTGCAATTGGTTTTAGAACCAATCCCGAACGGCAATTA
TGTCAGTCAATTGATGAAGTTTGGGCCTACATTGAAGAATACCATGAAAAGCGGAGCACT
TTGCCATACGAAATCGATGGAATTGTGATTAAAGTGAACGAATTTGCGTTGCAAGATGAA
TTAGGTTTCACTGTCAAAGCACCTCGCTGGGCGATTGCCTACAAATTTCCACCAGAAGAA
GCAGAAACAGTAGTGGAAGATATTGAATGGACAATTGGGCGCACGGGGGTGGTCACTCCT
ACTGCGGTCATGGCTCCTGTACGAGTCGCGGGAACCACGGTTAGTCGGGCAAGTTTGCAT
AATGCAGATTTTATTCAAATGAAAGATATCCGTTTAAATGATCATGTTATTATTTACAAA
GCCGGCGATATTATCCCAGAAGTAGCGCAAGTGCTAGTTGAAAAACGTGCAGCCGATAGT
CAGCCTTATGAAATGCCGACACATTGTCCAATTTGTCATAGTGAGTTGGTGCATTTAGAT
GAGGAAGTGGCGTTACGTTGTATTAATCCAAAATGCCCTGCGCAAATTAAAGAAGGGCTG
AATCACTTTGTCTCACGAAACGCAATGAACATTGATGGCTTGGGGCCACGAGTGTTAGCA
CAAATGTATGACAAAGGATTAGTGAAAGACGTAGCGGATCTGTATTTCTTAACAGAAGAA
CAATTAATGACTTTGGATAAAATCAAAGAAAAATCAGCAAACAACATTTATACTGCCATT
CAAGGGAGTAAAGAAAACTCTGTCGAACGTTTGATTTTTGGCTTAGGGATTCGCCATGTG
GGGGCGAAAGCGGCGAAAATTTTAGCGGAGCATTTTGGTGATTTACCAACCTTAAGTCGT
GCAACCGCGGAAGAAATTGTGGCTTTGGATTCAATTGGCGAAACAATCGCAGACAGCGTT
GTGACGTATTTTGAAAATGAGGAAGTTCATGAATTAATGGCTGAACTGGAAAAAGCCCAA
GTGAACTTGACATATAAAGGTCTCCGGACAGAACAATTAGCAGAAGTGGAGTCACCTTTC
AAAGACAAAACAGTTGTTTTAACAGGAAAATTAGCGCAGTACACTCGCGAAGAAGCCAAA
GAAAAAATTGAAAATCTTGGTGGAAAAGTTACAGGGAGTGTTTCGAAAAAAACTGACATT
GTGGTTGCTGGCGAAGATGCAGGCAGTAAATTAACCAAAGCTGAAAGCTTAGGCGTGACC
GTTTGGAATGAACAAGAAATGGTCGATGCGTTAGATGCAAGTCATTTTTAA

# Drug_Target_4_General_Function:
Involved in DNA ligase (NAD+) activity

# Drug_Target_4_General_References:
12663927	Paulsen IT, Banerjei L, Myers GS, Nelson KE, Seshadri R, Read TD, Fouts DE, Eisen JA, Gill SR, Heidelberg JF, Tettelin H, Dodson RJ, Umayam L, Brinkac L, Beanan M, Daugherty S, DeBoy RT, Durkin S, Kolonay J, Madupu R, Nelson W, Vamathevan J, Tran B, Upton J, Hansen T, Shetty J, Khouri H, Utterback T, Radune D, Ketchum KA, Dougherty BA, Fraser CM: Role of mobile DNA in the evolution of vancomycin-resistant Enterococcus faecalis. Science. 2003 Mar 28;299(5615):2071-4.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
4491

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
75585

# Drug_Target_4_Name:
DNA ligase, NAD-dependent

# Drug_Target_4_Number_of_Residues:
676

# Drug_Target_4_PDB_ID:
1TAE

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00533	BRCT
PF03119	DNA_ligase_ZBD
PF03120	DNA_ligase_OB

# Drug_Target_4_Protein_Sequence:
>DNA ligase, NAD-dependent
MEQQPLTLTAATTRAQELRKQLNQYSHEYYVKDQPSVEDYVYDRLYKELVDIETEFPDLI
TPDSPTQRVGGKVLSGFEKAPHDIPMYSLNDGFSKEDIFAFDERVRKAIGKPVAYCCELK
IDGLAISLRYENGVFVRGATRGDGTVGENITENLRTVRSVPMRLTEPISVEVRGECYMPK
QSFVALNEEREENGQDIFANPRNAAAGSLRQLDTKIVAKRNLNTFLYTVADFGPMKAKTQ
FEALEELSAIGFRTNPERQLCQSIDEVWAYIEEYHEKRSTLPYEIDGIVIKVNEFALQDE
LGFTVKAPRWAIAYKFPPEEAETVVEDIEWTIGRTGVVTPTAVMAPVRVAGTTVSRASLH
NADFIQMKDIRLNDHVIIYKAGDIIPEVAQVLVEKRAADSQPYEMPTHCPICHSELVHLD
EEVALRCINPKCPAQIKEGLNHFVSRNAMNIDGLGPRVLAQMYDKGLVKDVADLYFLTEE
QLMTLDKIKEKSANNIYTAIQGSKENSVERLIFGLGIRHVGAKAAKILAEHFGDLPTLSR
ATAEEIVALDSIGETIADSVVTYFENEEVHELMAELEKAQVNLTYKGLRTEQLAEVESPF
KDKTVVLTGKLAQYTREEAKEKIENLGGKVTGSVSKKTDIVVAGEDAGSKLTKAESLGVT
VWNEQEMVDALDASHF

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
NAD(+) + (deoxyribonucleotide)(n) + (deoxyribonucleotide)(m) = AMP + nicotinamide nucleotide + (deoxyribonucleotide)(n+m)

# Drug_Target_4_SwissProt_ID:
Q837V6

# Drug_Target_4_SwissProt_Name:
DNLJ_ENTFA

# Drug_Target_4_Synonyms:
Not Available

# Drug_Target_4_Theoretical_pI:
4.73

# Drug_Target_4_Transmembrane_Regions:
None

#END_DRUGCARD DB03227
